Research
Hormonal
GLP-1 receptor agonists (e.g., Liraglutide, Exenatide) promote weight loss and improve glycemic control by mimicking incretin hormones, delaying gastric emptying, and increasing satiety, making them advantageous for obese T2DM patients.
GLP-1 agonists like Liraglutide are injectable medications that help lower blood sugar and promote weight loss. They work by mimicking a natural hormone that slows digestion and increases fullness. They are particularly useful for obese patients. Hypoglycemia risk is low unless taken with other specific diabetes drugs.
GoodSupportsHIGH confidence
GLP-1 analogs are contraindicated in renal failure... Liraglutide decreases body weight; the greatest weight loss resulted from treatment with liraglutide in combination with combined metformin/sulfonylurea (-3.24 kg with 1.8 mg liraglutide)... These drugs exhibit increased resistance to enzymatic degradation by DPP4.
Why this rating
Clinical review citing specific trial data for Liraglutide and Exenatide.
Source
Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
Arun Chaudhury et al. · Frontiers in Endocrinology · 2017
DOI 10.3389/fendo.2017.00006
narrative_reviewCited 1,474×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modifications, including moderate weight loss (approx 7% body weight) and regular exercise (150 min/week moderate intensity), are cost-effective in preventing or delaying the onset of diabetes and improving glycemic control.Strong
- Metformin is the first-line oral pharmacological treatment for Type 2 Diabetes Mellitus (T2DM) across all age groups, primarily by activating AMPK to inhibit hepatic gluconeogenesis and sensitizing peripheral tissues to insulin.Good
- SGLT2 inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin) lower blood glucose through an insulin-independent mechanism by blocking glucose reabsorption in the kidneys, providing modest weight loss and blood pressure reduction.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →